Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Työhuone: 4124 (B-stairs, 4th floor) ORCID-tunniste: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- MYC is not detected in highly proliferating normal spermatogonia but is coupled with CIP2A in testicular cancers (2016)
- Matters
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription (2016)
- Nature Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Optimized design and analysis of preclinical intervention studies in vivo (2016)
- Scientific Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Potential Role for Inhibition of Protein Phosphatase 2A Tumor Suppressor in Salivary Gland Malignancies (2016)
- Genes, Chromosomes and Cancer
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells (2016)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1 (2016)
- Biochemical Society Transactions
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery (2016)
- International Journal of Nanomedicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Tutkimusrahoituksen merkitys tieteentekijän näkökulmasta (2016)
- Duodecim
(D1 Artikkeli ammattilehdessä) - CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations (2015)
- Oncotarget
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance (2015)
- Oncotarget
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling (2015)
- Scientific Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells (2015)
- Cancer Research
(O2 Muu julkaisu ) - Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer (2015)
- Cancer Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Relevance Rank Platform (RRP) for functional filtering of high content protein-protein interaction data (2015)
- Molecular and Cellular Proteomics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Serine 62 phosphorylated MYC associates with nuclear lamins and its regulation by CIP2A is essential for regenerative proliferation (2015)
- Cell Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - ColonyArea: An ImageJ plugin to automatically quantify colony formation in clonogenic assays (2014)
- PLoS ONE
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo (2014)
- Cell Cycle
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Mesoporous silica nanoparticles with redox-responsive surface linkers for charge-reversible loading and release of short oligonucleotides (2014)
- Dalton Transactions
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Molecular pathways: Harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. (2014)
- Clinical Cancer Research
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target (2013)
- Cancer Research
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä)